Company news
Sichuan Biokin Pharmaceutical Co., Ltd. Class A (SSE:688506) news
Sichuan Biokin Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Feb 10, 2026: Announcement on Resolutions of the 1st Extraordinary General…
Press releases — page 2
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 9, 2026
Earnings Preannouncement for 2025
January 30, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
January 23, 2026
Announcement on Voluntary Disclosure of Acceptance of the Marketing Application for iza-bren (EGFR×HER3 dual-antibody ADC) for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
January 20, 2026
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
January 16, 2026
Biokin to Present at J.P. Morgan's 44th Annual Healthcare Conference
January 13, 2026
Announcement on Voluntary Disclosure of Inclusion of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma into the Priority Review Program
January 6, 2026
Announcement on Resolutions of the 5th Meeting of the 5th Board of Directors
December 30, 2025
Announcement on Proposed Application for Registration and Issuance of Debt Financing Instruments
December 28, 2025
Announcement on Voluntary Disclosure of Milestone Payment Received by Wholly-owned Subsidiary Systimmune and Bristol-Myers Squibb for the Global Strategic Cooperation Agreement of iza-bren
November 30, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 27, 2025
Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Iza-Bren (an EGFR×HER3 Bispecific Antibody-Drug Conjugate) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma
November 23, 2025
Announcement on Signing Strategic Cooperation Agreement with Bank of China Limited, Sichuan Branch
November 19, 2025
Announcement on Resolutions of the 3rd Meeting of the 5th Board of Directors
November 4, 2025
Announcement on Replacing Self-raised Funds Invested in Advance in Investment Projects Financed by Raised Funds and Paid for Issuance Fee with Raised Funds
October 26, 2025
Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC
October 22, 2025
Announcement on Publication of Post-hearing Information Package for H-shares
October 21, 2025
Announcement on Voluntary Disclosure of First Patient Dosed in Phase III Clinical Trial of T-Bren (HER2 ADC) for First-Line Treatment of Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with HER2 Mutations
October 20, 2025
Announcement on Voluntary Disclosure of Completion of 1st Subject Enrollment in Phase III Clinical Trials of T-Bren (HER2ADC) for HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
October 15, 2025
Announcement on Voluntary Disclosure of Triggering of Milestone Payment Conditions by Wholly-owned Subsidiary Systimmune and Bristol-Myers Squibb for the Global Strategic Cooperation Agreement of iza-bren
October 12, 2025
C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
October 11, 2025
Announcement on Voluntary Disclosure of Receipt of Clinical Trial Approval Notice for BL-ARC001 in the Treatment of Advanced Solid Tumors
October 8, 2025
Announcement on Using Raised Funds to Contribute Paid-in Capital for Wholly-owned Subsidiary to Implement Investment Projects Financed by Partial Raised Funds
September 30, 2025
Announcement on Re-Submitting Application for H-share Offering and Listing to Hong Kong Stock Exchange and Publishing Application Materials
September 29, 2025
Announcement on the Results of Issuing Stocks to Specific Objects and Changes in Share Capital
September 26, 2025
Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Dual Antibody ADC) for Injection for Patients with Locally Advanced or Metastatic Urothelial Carcinoma Being Included in the List of Drugs Granted Breakthrough Therapy Designation
September 25, 2025
Indicative Announcement on the Disclosure of the Report on the Issuance of A Shares to Specific Objects
September 18, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
September 12, 2025
Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Dual Antibody ADC) for Injection for Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Being Included in the List of Drugs Granted Breakthrough Therapy Designation
September 10, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 8, 2025
Announcement on Voluntary Disclosure of Inclusion of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma into the Priority Review Program
September 5, 2025
Announcement on Resolutions of the 23rd Meeting of the 4th Board of Directors
August 19, 2025
Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Bispecific ADC) Receiving Breakthrough Therapy Designation from the U.S. FDA for the Treatment of Advanced EGFR-Mutant Non-Small Cell Lung Cancer
August 18, 2025
Announcement on Obtaining Registration Approval from the China Securities Regulatory Commission for Issuing Shares to Specific Objects
August 7, 2025
Announcement on Voluntary Disclosure of Obtaining Approval Notice for Phase II Drug Clinical Trials of iza-bren (EGFR×HER3 Bispecific Antibody ADC) Combination Therapy in the Treatment of Various Advanced Renal Cell Carcinoma
July 14, 2025
Announcement on Approval of Application for Issuance of Shares to Specific Object from Shanghai Stock Exchange upon Review
July 13, 2025
Announcement on Voluntary Disclosure of Interim Analysis of the Phase III Clinical Trial of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma Meeting the Primary Endpoint
July 2, 2025
Announcement on Voluntary Disclosure of Completing Enrollment of the First Subject in Phase III Clinical Trial of BL-M07D1 (HER2 ADC) for Injection for Postoperative Adjuvant Therapy of HER2-Positive Breast Cancer with Residual Invasive Carcinoma after Neoadjuvant Therapy
June 23, 2025
Indicative Announcement on Reply to Letter of Review and Inquiry on Application Documents for Share Issuance to Specific Objects (Revised Draft)
June 13, 2025
Announcement on the Revision of the Plan for Issuing A-shares to Specific Objects and Related Documents
May 30, 2025